Jan 7 (Reuters) - The U.S. Food and Drug Administration said on Friday it shortened the stipulated time between the primary series of the Moderna COVID-19 vaccine and a booster dose by a month to at least five months for people aged 18 or above. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
Market Closed -
Other stock markets
|
After market 07:00:05 pm | |||
151.5 USD | +2.43% | 150 | -1.00% |
May. 30 | Health Care Stocks Steady -- Health Care Roundup | DJ |
May. 30 | News Highlights : Top Company News of the Day - Thursday at 3 PM ET | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.36% | 56.69B | |
-3.86% | 41B | |
+38.14% | 38.11B | |
-12.01% | 26.89B | |
+14.13% | 25.59B | |
-21.62% | 18.59B | |
+0.21% | 12.39B | |
+25.96% | 11.99B | |
+23.02% | 11.88B | |
-11.29% | 10.89B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- U.S. FDA cuts gap for Moderna COVID-19 booster dose to five months